Shares of Torrent Pharmaceuticals climbed over 4% during Monday’s trading session even after the company reported a decline in fourth-quarter net profit, as investors focused on strong revenue growth, robust operational performance, and momentum across key global markets.
The stock rose 4.11% to Rs 4,670.60 on the NSE and touched a fresh 52-week high of Rs 4,681.00 during the session. At around 9:57 AM, the stock was trading firmly higher with gains of Rs 184.40.
Torrent Pharmaceuticals on Friday, May 22, reported a 21.9% year-on-year decline in consolidated net profit to Rs 389 crore for Q4 FY26, compared to Rs 498 crore in the same quarter last year.
However, revenue from operations jumped 41.8% YoY to Rs 4,197 crore from Rs 2,959 crore, while EBITDA rose 40.7% to Rs 1,356 crore from Rs 964 crore in the year-ago period. EBITDA margin stood at 32% compared to 33% last year.
The company’s India business remained a major growth driver, with revenues rising 43% to Rs 2,215 crore. Torrent said its base business grew 15%, ahead of Indian Pharmaceutical Market growth of 10%, according to AIOCD PharmaTrac data.
The company also reported strong momentum across international markets. Brazil revenues increased 30% to Rs 455 crore, while US revenues rose 31% to Rs 396 crore. Germany revenues climbed 16% to Rs 333 crore despite supply disruptions at a third-party supplier.
Torrent Pharmaceuticals also highlighted the strong launch performance of Gx Semaglutide, which secured a 38% market share across oral and injectable formats, according to April 2026 PharmaTrac data.
The company has additionally sought shareholder approval to raise up to Rs 5,000 crore through equity issuance, including QIP and convertible instruments. Torrent also recommended a final dividend of Rs 9 per equity share for FY26 after previously paying an interim dividend of Rs 29 per share.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.